BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oramed Pharmaceuticals Inc. (ORMP.OB) Selected to Present at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL, June 21-25, 2013


3/22/2013 9:17:40 AM

JERUSALEM, March 21, 2013 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its abstract, titled "Dose response to oral insulin capsules in fasting, healthy subjects," has been selected for a poster presentation at the 73rd Scientific Sessions of the American Diabetes Association, being held on June 21-25, 2013, in Chicago, IL, USA. In addition, the work was selected to be showcased in the Scientific Session's Innovative Oral Agents - Innovative Discoveries Guided Audio Poster Tour, to be held on Monday, June 24, 2013. This 50-min tour presents and provides a moderated discussion of 7-8 posters in efforts to expose meeting attendees to particularly novel or recent developments in the field.

About the American Diabetes Association (ADA) Scientific Sessions

The ADA's Scientific Sessions brings together scientists and health care professionals from around the world who are involved in diabetes research and care. The five-day meeting features the most timely and significant advances in the prevention, diagnosis, and treatment of diabetes. The program is organized into eight distinctive theme areas and includes presentation by world-renowned diabetes experts.

For more information on the ADA, please refer to their website: http://www.diabetes.org

More information on the Scientific Sessions can be found here.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES